GNCA (GNCA) has the following price history information. Looking back at GNCA historical stock prices for the last five trading days, on May 26, 2022, GNCA opened at $0.08, traded as high as $0.09 and as low as $0.07, and closed at $0.07. Trading volume was a total of 33.81M shares. On May 27, 2022, GNCA opened at $0.07, traded as high as $0.07 and as low as $0.06, and closed at $0.06. Trading volume was a total of 19.12M shares. On May 31, 2022, GNCA opened at $0.05, traded as high as $0.07 and as low as $0.05, and closed at $0.06. Trading volume was a total of 26.95M shares. On June 01, 2022, GNCA opened at $0.06, traded as high as $0.07 and as low as $0.06, and closed at $0.06. Trading volume was a total of 15.63M shares. On June 02, 2022, GNCA opened at $0.06, traded as high as $0.06 and as low as $0.05, and closed at $0.05. Trading volume was a total of 10.04M shares.

GNCA Historical Stock Prices By Date:

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 20142015201620172018201920202021202220232024

Below, we examine the compound annual growth rate — CAGR for short — of an investment into GNCA shares, starting with a $10,000 purchase of GNCA, and working forward through the historical stock price information to today.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	04/28/2014
End date:	06/02/2022
Start price/share:	$150.96
End price/share:	$0.05
Dividends collected/share:	$0.00
Total return:	-99.97%
Average Annual Total Return:	-62.72%
Starting investment:	$10,000.00
Ending investment:	$3.38
Years:	8.10

GNCA Historical Price Range
Date	Open	High	Low	Close	Volume
05/26/2022	$0.08	$0.09	$0.07	$0.07	33.81M
05/27/2022	$0.07	$0.07	$0.06	$0.06	19.12M
05/31/2022	$0.05	$0.07	$0.05	$0.06	26.95M
06/01/2022	$0.06	$0.07	$0.06	$0.06	15.63M
06/02/2022	$0.06	$0.06	$0.05	$0.05	10.04M

About GNCA

Genocea Biosciences is a biopharmaceutical company that discovers and develops cancer immunotherapies using its ATLAS™ platform. The ATLAS platform profiles each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Co.'s GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral cells (NPTs). The GEN-011 NPTs are specific for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived, tumor-specific T cell therapy. Co.'s GEN-009 program is a neoantigen vaccine delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens.

GNCA Historical Closing Prices
Date	Close
05/26/2022	$0.07
05/27/2022	$0.06
05/31/2022	$0.06
06/01/2022	$0.06
06/02/2022	$0.05

Healthcare Historical Prices

GNCA is categorized under the Healthcare sector; below are some other companies in the same sector: GNMK Historical Stock Prices GNMX Historical Stock Prices GNOW Historical Stock Prices GNVC Historical Stock Prices GRFS Historical Stock Prices GSK Historical Stock Prices GTHX Historical Stock Prices GTIV Historical Stock Prices GTS Historical Stock Prices GTXI Historical Stock Prices Also explore: GNCA shares outstanding history Free GNCA Email Alerts: Get Dividend Alerts Get SEC Filing Alerts

GNCA Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.